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CADM1 inhibits squamous cell 
carcinoma progression by reducing 
STAT3 activity
Sabari Vallath, Elizabeth K. Sage, Krishna K. Kolluri, Sofia N. Lourenco, Vitor S. Teixeira, 
Suneeta Chimalapati, P. Jeremy George, Sam M. Janes & Adam Giangreco
Although squamous cell carcinomas (SqCCs) of the lungs, head and neck, oesophagus, and cervix 
account for up to 30% of cancer deaths, the mechanisms that regulate disease progression remain 
incompletely understood. Here, we use gene transduction and human tumor xenograft assays to 
establish that the tumour suppressor Cell adhesion molecule 1 (CADM1) inhibits SqCC proliferation and 
invasion, processes fundamental to disease progression. We determine that the extracellular domain 
of CADM1 mediates these effects by forming a complex with HER2 and integrin α6β4 at the cell surface 
that disrupts downstream STAT3 activity. We subsequently show that treating CADM1 null tumours 
with the JAK/STAT inhibitor ruxolitinib mimics CADM1 gene restoration in preventing SqCC growth 
and metastases. Overall, this study identifies a novel mechanism by which CADM1 prevents SqCC 
progression and suggests that screening tumours for loss of CADM1 expression will help identify those 
patients most likely to benefit from JAK/STAT targeted chemotherapies.
Invasive, metastatic squamous cell carcinomas (SqCCs) of the lungs, head and neck, oesophagus, and cervix are 
responsible for over 400,000 deaths per year1. SqCC progression involves acquisition of epithelial-to-mesenchymal 
transition (EMT) phenotypes including enhanced tumour cell motility, increased cell proliferation, elevated 
cell invasiveness, and reduced cell adhesiveness, all of which contribute to uncontrolled tumour growth and 
multi-organ metastases2. These changes are accompanied by increased MMP production, reduced E-cadherin 
protein abundance, and elevated Twist1 and Snail expression3–5. Although they occur in distinct organs, the char-
acteristics of human SqCCs are conserved and frequently involve mutations in TP53, PTEN, LKB1 and SOX26. 
Despite this, a comprehensive understanding of the mechanisms that drive human SqCC progression remains 
elusive.
Cell adhesion molecule 1 (CADM1, also known as Necl2, TSLC1, IGSF4, RA175, and SynCam), an 
Immunoglobulin superfamily (Igsf) adhesion molecule, is a well-known tumour suppressor for a variety of can-
cers of epithelial origin7. CADM1 downregulation through epigenetic silencing or loss of heterozygosity accom-
panies increased tumour cell invasion and metastatic potential, making it an attractive candidate for regulating 
SqCC progression8–10. In lung adenocarcinoma CADM1 inhibits tumour cell proliferation via cytoplasmic band 
4.1 and MAGuK protein interactions11. In contrast, the tumour suppressive effects of CADM1 in breast ade-
nocarcinoma are dependent upon T cell–mediated immune surveillance12,13. In immortalized kidney cells, the 
extracellular domain of CADM1 binds the receptor tyrosine kinase HER3, reducing cell proliferation14. Finally, 
in colon adenocarcinoma CADM1 regulates hemidesmosome stability by increasing integrin α 6β 4 interactions, 
thereby reducing tumour cell motility15. Thus, the mechanisms by which CADM1 regulates disease progression 
are highly dependent on the tumour and tissue type in which it is expressed.
In this study we use patient samples, cell lines, and human tumour xenograft models to define a key functional 
role for CADM1 in SqCC progression. We demonstrate that the extracellular domain of CADM1 restricts tumour 
growth and metastases by interacting with HER2 and integrin α 6β 4 at the cell surface. We establish that this 
CADM1-HER2-Itgα 6β 4 signaling complex reduces downstream STAT3 activity, an important regulator of SqCC 
proliferation and invasion. We also show that disrupting STAT3 signaling with the JAK1/2 inhibitor ruxolitinib 
replicates these effects specifically in CADM1-null disease. These results suggest that screening SqCC tumours 
for loss of CADM1 expression will help identify patients at greatest risk of disease progression and most likely to 
benefit from JAK/STAT targeted chemotherapies.
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Materials and Methods
Human tissue samples. Human tissue samples were obtained via video chip flexible auto fluorescence 
bronchoscopy with full informed consent from all subjects in accordance with UK and University College 
Hospital research ethical guidelines (REC Approval No. 06/Q0505/12). All sample collection was approved by 
University College Hospital Research ethics committee. Briefly, samples were identified using fluorescence imag-
ing, biopsied, fixed, and processed for pathological diagnosis as previously described16. For immunostaining, 
samples were formalin fixed, paraffin embedded (FFPE), and sectioned at 5 μm. This study was carried out in 
accordance with the Declaration of Helsinki (2000) of the World Medical Association.
Cell culture and viral transduction. A431 cells were transduced with a constitutively active luciferase 
reporter and a doxycycline-inducible CADM1-FLAG-IRES-GFP lentivirus. FLAG-tagged CADM1 con-
structs including full length, extracellular (∆ EC), and cytoplasmic (∆ CP) domain deletion isoforms were pro-
vided by Prof. Y Takai and generated as previously described14,15. CADM1 constructs were then cloned into a 
doxycycline-inducible lentivirus as previously described14,17. Luciferase lentivirus was obtained from Addgene 
for in vivo tracking studies. Lentivirus production, transduction, and cellular selection were performed according 
to standard conditions17. The A431 SqCC cell lines were obtained from ATCC and validated using STR profiling 
(LGC standards). Cells were maintained in DMEM (Sigma) plus 10% FBS and glutamine. Recombinant EGF was 
provided to cells used in immunoblot studies.
Human Tumorigenesis Studies. In vivo tumorigenesis studies were performed in accordance with UK 
Home Office guidelines under license 70/7607. All experiments were approved by University College London 
Biological Safety and Biological resource ethics committees. Luciferase expressing SqCC cells (105/animal) were 
injected into the tail vein of NSG mice and tumour engraftment assessed by measuring luciferase activity. Mice 
were randomized such that tumour burden was balanced for each group. Doxycycline (1 mg/ml) was adminis-
tered to the drinking water from day 0. Administration of ruxolitinib (2.5 mg/animal in 100 ul water) was per-
formed daily beginning on day five after administration of human tumour cells; drug was administered via oral 
gavage. Quantification of tumour burden and metastatic spread was assessed by monitoring luciferase activity 
via IVIS imaging on a weekly basis following 200 μl intraperitoneal injections of 2 mg/ml D-luciferin (Regis). 
Animals were injected with 10 mg/kg BrdU 1 hour prior to sacrifice.
Migration assay. Single SqCC cell suspensions (5 × 104 cells in α MEM/0.1%BSA) were pre-treated with 
drug or antibody for 1 hour at 4 °C, seeded onto 8 μm Transwell inserts (Corning), and incubated for 16 hours at 
37 °C in media containing drugs or antibodies as indicated. Inserts were formalin fixed, stained with 1% crystal 
violet, and imaged to assess cell migration. Stained, migrated cells were subsequently dissolved in 10% glacial 
acetic acid with migrated cell abundance quantified by UV-VIS spectroscopy.
Proliferation assay. Cells (5 × 104 in DMEM/10%FBS) were grown as indicated and XTT metabolic activity 
(corresponding to total cell abundance) was determined as per the manufacturer’s instructions (Promega, UK).
Biochemical Methods. Cells were lysed in RIPA (Sigma) or immunoprecipitation lysis buffer (Thermo 
fisher) for immunoblotting and immunoprecipitation. Antibodies used were directed against CADM1 (chicken, 
MBL), FLAG (M2, Sigma Aldrich), ITGA6 (rabbit, R&D, Abcam), ITGB4 (Abcam), HER2 (Rabbit, Abcam), 
HSC70 (Santa Cruz), phospho-STAT3, total STAT3 (Cell Signalling), and tubulin (Cell signaling). For immuno-
precipitation experiments, cell lysates (500 μg) were blocked, incubated with antibodies directed against FLAG 
(to pull down CADM1), HER2, or integrin α 6, mixed with Protein A beads, washed and immunoprecipitated 
according to described methods14,15.
Immunostaining. Paraffin embedded sections of human and murine tissues were subjected to haematoxylin 
and eosin (H&E) or immunofluorescence staining with antibodies directed against keratin 5 (rabbit, Abcam), 
CADM1 (chicken, MBL), E-cadherin (HECD1, mouse, Abcam), BrdU (rat, Abcam), Luciferase (rabbit, Abcam), 
keratin 14 (rabbit, Covance), and phospho-STAT3 (Cell Signalling). Detection of apoptotic cells was via TUNEL 
staining (Promega). Immunostained cells were fixed using 4% paraformaldehyde and incubated with antibodies 
to CADM1 (chicken, MBL), ITGA6 (rabbit, R&D), and HER2 (Rabbit, Cell Signalling).
Statistical analyses. Statistical analysis was performed using GraphPad Prism Software (La Jolla, CA). A 
student’s t test was applied for comparisons between two groups (unpaired, two tailed). Two-way ANOVA with 
Bonferroni post-test analyses were used to compare differences in tumour growth over time between each group.
Results
CADM1 loss is associated with increased SqCC progression. Previous studies have demonstrated 
that loss of CADM1 occurs in a majority of human SqCCs8–10. We verified these findings by analyzing CADM1 
gene expression in normal and SqCC tissue samples representing lung, head and neck, oesophageal, and cervi-
cal cancers accessed through Oncomine (www.oncomine.org). Analysis of lung (Bhattacharjee), head and neck 
(TCGA), oesophagus (Su), and cervical SqCC (Zhai) datasets revealed significant reductions in CADM1 expres-
sion in all tumour samples relative to controls (Fig. 1A). A separate comparison of CADM1 gene expression in 
3 normal keratinocyte (KJ, KV, KY) and 8 established SqCC cell lines (A431, SCC9, SCC12b, SCC13, SCC15, 
SCC27, SCC66, SCC71) revealed significant (> 80%) or complete loss of CADM1 in 6 of 8 tumour cell lines com-
pared with controls (Supplemental Figure 1).
To establish whether loss of CADM1 was specifically associated with SqCC progression we examined protein 
expression using a unique biobank of normal, static, and progressive SqCC samples obtained via autofluorescence 
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bronchoscopy18,19. In some cases, patients’ lungs were under continuous surveillance for up to 10 years with no 
evidence of disease progression (static SqCC). In other cases patients’ tumours underwent rapid progression 
Figure 1. Loss of CADM1 is associated with squamous cell carcinoma progression. (A) Oncomine 
analysis of CADM1 expression in lung (Bhattacharjee), head and neck (TCGA), oesophagus (Su), and 
cervical (Zhai) SqCC datasets. Sample size (n), CADM1 gene rank, and p-values are shown for each tumour 
type. (B) Representative normal (n = 8), static (n = 9) and progressive (n = 10) lung SqCC biopsy specimens 
stained for keratin 5 (K5, red) plus CADM1 (green), or CADM1 (green) and E-cadherin (red). Scale bars are 
100 μm (B) error bars denote standard error of the mean (A).
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within 6–12 months (progressive SqCC). We identified epithelial tissues based on keratin 5 (Krt5) immunos-
taining (red, Fig. 1B) and assessed CADM1 and E-cadherin protein abundance in histologically normal lung 
(n = 8), static (n = 9), and progressive (n = 10) SqCC samples (green, Fig. 1B). In all normal lung and static 
SqCC biopsies, CADM1 and E-cadherin were readily detected throughout epithelial tissues (8/8 normal; 9/9 
static SqCC samples; green, Fig. 1B). In contrast, CADM1 and E-cadherin staining were undetectable in the 
majority of progressive SqCC biopsies (8/10 lacking CADM1; 7/10 lacking E-cadherin; green, Fig. 1B). These 
results demonstrate that loss of CADM1 is associated with SqCC progression and coincides with the acquisition 
of EMT phenotypes including reduced E-cadherin expression.
CADM1 inhibits SqCC cell growth and metastases. To determine whether CADM1 expression 
inhibits SqCC progression we studied its effects on the growth and migration of the CADM1-null SqCC cell 
line A431. Cells were transduced with a constitutively active luciferase reporter and a doxycycline-inducible 
CADM1-FLAG-IRES-GFP lentivirus cloned from a plasmid originally supplied by Prof. Y. Takai (Supplemental 
Figure 2). Doxycycline treatment of CADM1 transduced cells restored CADM1 gene and protein expression 
to physiologically relevant levels that were similar to those of noncancerous squamous epithelial cells (primary 
keratinocytes, Fig. 2A,B). In the absence of doxycycline, the growth and migration capacities of CADM1 trans-
duced cells were indistinguishable from untransduced SqCC controls (data not shown). DNA cell cycle analysis of 
CADM1 transduced, doxycycline treated cells revealed that CADM1 restoration promoted accumulation of cells 
at the G0/G1 cell cycle checkpoint and reduced the number of S phase cells (Fig. 2C). In contrast, CADM1 expres-
sion had no effects on either SqCC cell death or apoptosis (Fig. 2D). Using transwell migration assays, we assessed 
the in vitro migration potential of CADM1 expressing tumour cells. Increased numbers of wildtype SqCC cells 
underwent transwell migration compared with doxycycline treated, CADM1-expressing cells (Fig. 2E).
To establish whether CADM1 inhibits SqCC progression in vivo we developed a human tumour xenograft 
model in which control or CADM1 expressing A431 cells were transplanted into immunocompromised mice 
by intravenous tail vein injection (n = 8 mice/tumour type). SqCC growth and metastases were monitored using 
noninvasive bioluminescent luciferase imaging. Immediately post injection, comparable luciferase signal strength 
was detected exclusively in the lungs of A431 control and A431-CADM1 tumour bearing mice (Fig. 3A,B). 
Longitudinal imaging demonstrated reduced SqCC growth in CADM1 expressing tumours relative to controls 
(p = 0.0001; Fig. 3A,B). Open imaging also revealed significantly fewer SqCC metastases in A431-CADM1 
tumour bearing mice compared with untransduced SqCC controls (p = 0.0076; Fig. 3A,C). H&E and BrdU 
staining demonstrated reductions in A431-CADM1 tumour size and cell proliferation (Fig. 3D,E). As above, 
TUNEL staining revealed no differences in tumour cell apoptosis upon CADM1 reintroduction (Fig. 3D,E). Thus, 
CADM1 inhibits SqCC progression both in vitro and in vivo by reducing cell proliferation and invasion.
The extracellular domain of CADM1 regulates SqCC progression. Conflicting evidence surrounds 
the relative importance of the extracellular (EC) versus cytoplasmic (CP) signaling domains of CADM1 in regu-
lating tumour progression11,14,15. To identify whether EC or CP domains of CADM1 regulate SqCC growth and 
metastases, we transduced A431 cells with CADM1 mutant constructs lacking either their extracellular (∆ EC) or 
cytoplasmic (∆ CP) signaling domains (originally described in14,15, Fig. 4A). CADM1-ΔEC expression resulted in 
SqCC growth and migration that was indistinguishable from untransduced CADM1-null controls (compare blue 
and black lines and bars, Fig. 4B,C). In contrast, the growth and migration of CADM1-ΔCP expressing cells was 
equivalent to that of full length CADM1 expressing cells (compare red and green bars and lines; Fig. 4B,C). As 
above, we used a human tumour xenograft model to assess CADM1-ΔCP and CADM1-ΔEC growth and metas-
tases in vivo. Consistent with our in vitro results, longitudinal and open imaging demonstrated that CADM1-ΔCP 
tumours grew at a reduced rate and with fewer metastases per mouse when compared with CADM1-ΔEC 
tumours (*p < 0.01; n = 6 animals/cell type; Supplemental Figure 3).
To validate these results, we analyzed the expression of key CADM1 cytoplasmic signaling proteins CASK and 
DAL-1 in control, CADM1, ΔCP and ΔEC cell lines. As expected, there were no significant differences in CASK 
or DAL-1 expression between any of these cell types (Fig. 4D). These results confirm that the extracellular portion 
of CADM1 regulates SqCC progression independent of cytoplasmic CASK and DAL-1 signaling.
Earlier studies have demonstrated that the extracellular domain of CADM1 can interact with both integrin 
α 6β 4 and HER214,15. To identify whether one or more of these interactions might regulate SqCC progression, we 
used integrin α 6 and CADM1 immunoprecipitation (IP) assays. In SqCC controls, Itgα 6, integrin β 4 (Itgβ 4), 
and HER2 formed a HER2-Itgα 6-Itgβ 4 protein complex independent of CADM1 expression (Fig. 4E; uncropped 
cell lysate blots in Supplemental Figure 4). In contrast, immunoprecipitation of CADM1 expressing cells using an 
anti-FLAG antibody demonstrated the presence of an additional complex involving CADM1, Itgα 6, Itgβ 4, and 
HER2 (Fig. 4E). All IP experiments were performed twice using independently generated cell lysates.
To determine which of the specific interactions between CADM1, HER2, and Itgα 6β 4 influenced SqCC 
growth and metastases, cells were treated with Lapatinib, a small molecule inhibitor of HER2, and GoH3, a mon-
oclonal antibody that blocks the functional domain of integrin α 6. Lapatinib treatment reduced the growth of 
untransduced SqCC cells to a level identical to that of CADM1 expressing cells but had no effect on cell migration 
(black, Fig. 4F,G). In contrast, GoH3 had no effect on control SqCC cell growth but did reduce cell migration 
(black, Fig. 4H,I). Neither Lapatinib nor GoH3 had any effects on SqCC cell growth or migration when CADM1 
was expressed, confirming the specificity of these effects to CADM1-null cells (red, Fig. 4F–I). These results sug-
gest that CADM1 inhibits SqCC growth and motility through a mechanism involving both HER2 and Itgα 6β 4 
downstream signaling.
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Figure 2. CADM1 expression reduces in vitro SqCC growth and migration. (A,B) Representative image (A) 
and protein immunoblot (B) of doxycycline treated wildtype and CADM1 transduced A431 cells. (C) Propidium 
iodide staining and quantification of cell cycle phase in control and CADM1 expressing cells. (D) DAPI and 
Annexin V staining and quantification of cell death and apoptosis in A431 control and CADM1 expressing SqCC 
cells. (E) Representative images of SqCC transwell migration and quantification of relative control and CADM1 
expressing cell migration. Scale bars are 100 μm (A,E); asterisks denote significance of p < 0.005 (**); error bars 
denote standard error of the mean.
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CADM1 inhibits SqCC progression by reducing STAT3 activity. It has previously been shown that 
Itgα 6β 4 can cooperate with HER2 to drive downstream STAT3 phosphorylation and signaling20,21. We therefore 
examined whether CADM1 interactions with HER2 and Itgα 6β 4 in SqCC might regulate STAT3 phosphoryla-
tion. Untransduced and CADM1-expressing A431 cells were grown to 70% confluence, serum starved overnight, 
and treated with EGF for 15 minutes to induce STAT3 activation prior to immunoblotting. Phospho-specific 
tyrosine 705 (pY705) STAT3 staining and ImageJ quantification demonstrated that CADM1 expression reduced 
A431 STAT3 phosphorylation levels to 41 ± 6% of untransduced controls (n = 3, Fig. 5A). We also observed a 
complete lack of phospho-STAT3 staining in CADM1-expressing SqCC tumour xenografts (red, Fig. 5B). This 
difference between in vitro and ex vivo A431-CADM1 STAT3 activity may relate to fundamental differences in 
these two model systems.
To examine whether CADM1 expression might inhibit SqCC progression via direct STAT3 inhibition, 
CADM1 null, CADM1 transduced, and endogenous CADM1 expressing SqCC cells were treated with the clini-
cally approved JAK/STAT inhibitor, ruxolitinib. In CADM1 null A431 cells, ruxolitinib treatment reduced both 
in vitro cell growth and migration (black, Fig. 5C,D). In contrast, ruxolitinib treatment had no effects on CADM1 
transduced A431 cells, verifying the specificity of these effects in SqCC cells lacking CADM1 (red, Fig. 5C,D). In 
a SqCC cell line with low endogenous CADM1 expression (SCC15, Supplemental Figure 1), ruxolitinib treatment 
significantly reduced cell growth but had no effect on cell migration (black, Fig. 5E,F). In two further SqCC cell 
lines with robust endogenous CADM1 expression (SCC9 and SCC13, Supplemental Figure 1), ruxolitinib treat-
ment had no effect on either SqCC cell growth or migration (red and blue lines, Fig. 5E,F). These results suggest 
that endogenous CADM1 expression determines tumour ruxolitinib sensitivity, although other pathways may 
also be involved.
Based on our in vitro results, we investigated whether in vivo treatment with the JAK/STAT inhibitor ruxol-
itinib could mimic the effects of restoring CADM1 expression on reducing CADM1-null SqCC progression. As 
before, we used a tumour xenograft model of luciferase transduced, CADM1 negative and CADM1 expressing 
A431 SqCC cells. Longitudinal tumour imaging revealed that ruxolitinib significantly and specifically reduced 
CADM1-null SqCC growth and metastases to a level that was indistinguishable from CADM1 expressing cells 
Figure 3. CADM1 inhibits SqCC progression. (A) Representative luciferase images of SqCC growth and 
metastatic burden in CADM1 negative (Control) and CADM1 expressing (CADM1) human tumour xenografts. 
(B,C) Quantification of tumour growth (% of luciferase signal relative to day 0, (B)) and metastatic burden 
(number of metastases/mouse, (C)) in control and CADM1 tumour xenografts (n = 8/cell type). (D) Sections 
of control and CADM1-expressing tumours stained with H&E, BrdU (red), luciferase (green), and TUNEL 
(green). (E) Quantification of BrdU(+ ) and TUNEL(+ ) cell abundance in control (black) and CADM1 
expressing (red) tumours. Scale bars are 100 μm (D) error bars denote standard error of the mean.
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Figure 4. The extracellular domain of CADM1 determines SqCC progression. (A) Schematic of full length, 
extracellular (CADM1-ΔEC) and cytoplasmic (CADM1-ΔCP) domain deletion constructs. (B,C) In vitro 
control, CADM1, CADM1-∆ EC and CADM1-∆ CP expressing cell proliferation (B) and migration (C).  
(D) Immunoblot of CASK and Dal-1 abundance in A431 control, Cadm1, ΔEC, and ΔCP expressing cell 
lines. (E) Immunoprecipitation (IP) of control and CADM1-expressing SqCC lysates using anti-FLAG and 
anti-ITGα 6 antibodies. IP and total cell lysates were probed with antibodies as indicated. (F–I) Graphs of 
control (A431) and CADM1-expressing SqCC proliferation (F,H) and cell migration (G,I) following treatment 
with Lapatinib (F,G) or GoH3 (H,I). n = 3 per cell type and assay (B,C,F–I); asterisks denote significance 
of p < 0.005 (**) or p < 0.001 (***); error bars denote standard error of the mean. IP experiments (E) were 
performed twice using independent cell lysates.
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(Fig. 6A–C). Further H&E and BrdU staining analysis demonstrated that treatment with ruxolitinib achieved this 
effect by reducing SqCC proliferation (Fig. 6D,E).
To establish whether endogenous CADM1 expression could influence in vivo SqCC sensitivity to JAK/STAT 
inhibition we generated human tumour xenografts using the SqCC lines SCC9 and SCC13. Consistent with our 
in vitro results, ruxolitinib treatment had no effect on either the growth or metastatic potential of SCC9 and 
SCC13 tumour xenografts (Fig. 6F–H and data not shown). These results demonstrate that treatment with the 
JAK/STAT inhibitor ruxolitinib might only be an effective therapy in SqCC tumours that lack endogenous 
CADM1 expression.
Figure 5. CADM1 reduces SqCC STAT3 activity. (A,B) Immunoblot (A) and immunofluorescent staining 
((B), red) of active STAT3 (pY705) abundance in control and CADM1-expressing SqCC. (C,D) Graphs of 
control (A431) and CADM1-expressing SqCC proliferation (C) and cell migration (D) following treatment 
with 10 μm ruxolitinib. (E,F) Proliferation (E) and migration (F) of three additional, endogenous CADM1-
expressing SqCC cell lines (SCC9, red; SCC13, blue; SCC15, black) in the absence (solid lines) or presence 
(dashed lines, hollow boxes) of ruxolitinib treatment. Error bars represent SEM (n = 4/condition); asterisks 
denote significance of p < 0.005 (**). STAT3 immunoblots are representative of n = 3 independent experiments.
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Figure 6. CADM1-null SqCC are sensitive to JAK/STAT chemotherapy. (A) Representative images of SqCC 
growth and metastatic burden in human tumour xenografts following treatment with ruxolitinib or restoration 
of CADM1 expression (n = 6/treatment type). (B,C) Quantification of SqCC growth (B) and metastatic burden 
(C) in control (black), CADM1 expressing (red), and ruxolitinib treated tumours (blue). (D) Control, CADM1-
restored, and ruxolitinib treated tumour sections stained with H&E, BrdU (red), and luciferase antibodies 
(green). (E) Quantification of BrdU(+ )cell abundance in control (black), CADM1 expressing (red), and 
ruxolitinib treated tumours (blue). (F) SCC9 tumour size and metastatic burden in human tumour xenografts 
with or without ruxolitinib treatment. (G,H) Quantification of SCC9 tumour growth (G) and metastatic 
burden (H) in the absence (black, n = 7) or presence of ruxolitinib (blue, n = 7). Scale bars are 100 μm (D) 
asterisks denote significance of p < 0.005 (**) or p < 0.001 (***); error bars denote standard error of the mean.
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Discussion
Despite recent advances in murine models for human SqCC, an understanding of the mechanisms that drive 
tumour progression remains elusive. Here, we demonstrate that CADM1 inhibits SqCC progression via a mech-
anism involving HER2 and ITGα 6β 4-mediated STAT3 inhibition (Fig. 7).Our results indicate that the extracel-
lular domain of CADM1 is responsible for suppressing tumour progression, consistent with previous studies of 
human colorectal cancer cells14,15. Using tumour xenograft studies, we demonstrate that the extracellular domain 
of CADM1 regulates SqCC progression via generation of a HER2-ITGα 6β 4-CADM1 complex at the cell surface 
that inhibits HER2-ITGα 6β 4 mediated STAT3 phosphorylation. We also establish that treating CADM1 negative 
cancer cells with the clinically approved JAK/STAT inhibitor ruxolitinib can reduce in vitro and ex vivo tumour 
growth and metastases. These results suggest that screening human SqCCs for CADM1 expression may not only 
help identify patients at risk of disease progression but also distinguish those people most likely to benefit from 
JAK/STAT targeted chemotherapies.
There is a significant, growing interest in the use of JAK/STAT and STAT3-specific therapies to treat human 
SqCC. In preclinical and early phase clinical studies, STAT3 oligonucleotide decoys as well as JAK small molecule 
inhibitors have shown promise in head and neck, lung, and other SqCC types22–24. Despite this, separate studies 
suggest that STAT3 may also play a tumour suppressive role in some cancers25,26 and that STAT3 deletion can in 
fact promote lung adenocarcinoma formation27. In light of this, ours is the first study to demonstrate that loss 
of endogenous CADM1 expression may serve as a novel biomarker for determining JAK/STAT chemotherapy 
responsiveness.
Our results may explain why single chemotherapy agents that target receptor tyrosine kinases such as HER2 
have largely proven ineffective in treating SqCC28. Specifically, our discovery that inhibiting either HER2 or 
ITGα 6β 4 alone is ineffective at blocking in vitro SqCC growth and migration suggests that targeting either mol-
ecule on its own may inadvertently promote downstream STAT3 activity. In support of this possibility, previous 
studies have shown that integrin α 6β 4 cooperates with HER2 to drive STAT3 activation during tumour progres-
sion20. It has also recently been shown that single pharmacological inhibitors of EGFR, MEK, PI3K and FGFR 
increase both STAT3 activity and tumour metastases in various cancer models29–31.
Although our study establishes that CADM1 inhibits SqCC progression, the mechanisms driving the ini-
tial loss of CADM1 expression remain incompletely understood. In many human cancers, CADM1 silencing 
occurs following promoter methylation and loss of chromosomal heterozygosity8–10. Increased transcription of 
the miRNA cluster encoding miR-214 and miR-199 has also been shown to reduce CADM1 expression via loss of 
ST6GAL1-dependent CADM1 sialylation32. Interestingly, transcription of this miRNA cluster is itself regulated 
by TWIST1, an EMT biomarker associated with SqCC progression and canonical Wnt/β -catenin target gene acti-
vation33,34. Given that we have recently shown that SqCC pathogenesis is associated with increased Wnt/β -catenin 
signaling16, we believe a process involving increased Wnt/β -catenin, acquisition of EMT phenotypes, and reduced 
ST6GAL1-dependent sialylation is a plausible mechanism to drive epigenetic loss of CADM1 in human SqCC.
In previous studies, CADM1 has been shown to promote immune surveillance via a mechanism involv-
ing Class 1 restricted, T cell associated molecule (CRTAM) engagement12,13,35. In the current study, our use of 
immunocompromised mouse models excludes a role for CADM1-CRTAM interactions in regulating SqCC pro-
gression. However, we speculate that in human patients CRTAM-dependent immune surveillance of CADM1 
expressing tumours may provide an additional mechanism by which CADM1 suppresses tumour growth. 
Interestingly, immune surveillance is emerging as a key factor in SqCC ontogeny28,36, with increased expression 
of PD-1, PD-L1, and CTLA-4 reducing immune surveillance in multiple tumour types12,13,36–38. Consistent with 
Figure 7. Model of CADM1 activity in SqCC. In CADM1-null tumours HER2 and ITGα 6β 4 cooperate to 
drive STAT3-mediated tumour growth and metastases. CADM1 promotes a CADM1-HER2-ITGα 6β 4 ternary 
complex that suppresses downstream STAT3 activity thereby inhibiting cell proliferation and migration. 
Ruxolitinib mimics the effects of CADM1 in suppressing HER2-ITGα 6β 4 mediated STAT3 activity.
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this, clinical trials involving PD-1, PD-L1 and CTLA4 monoclonal antibody therapies have recently shown prom-
ise in patients with SqCC28,37. In light of these findings, our data suggests that combinatorial therapies involving 
increased immune surveillance (perhaps via CTLA-4, PD-1, or PD-L1 inhibition) coupled with targeted JAK/
STAT chemotherapies may prove beneficial in patients with CADM1 negative disease.
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